Nanobiotix (NBTX) Stock News
$NBTX · NASDAQ · HEALTHCARE · 1 stories in 30 daysBORSA has published 1 story on Nanobiotix (NBTX) in the past 30 days. BORSA’s news read on NBTX is leaning bullish at 57/100, −1 over 24 hours, based on 1 company event over the past 30 days. NBTX last closed at $22.90 on Oct 8, down 17.92% over five sessions and down 37.50% over the past month. Nanobiotix last reported quarterly results on Sep 29, 2026, for the quarter ended Jun 30, 2026.
The wire on $NBTX
newest first · updated · direct subject stories onlyNanobiotix reported a first-half 2026 net loss of EUR34.3 million, or EUR0.70 per share, compared with a loss of EUR5.4 million a year earlier. Cash and equivalents stood at EUR110.9 million at June 30, extended by an oversubscribed EUR86 million follow-on offering. The company highlighted early clinical data from its JNJ-1900 (NBTXR3) program in NSCLC and received FDA clearance for a Phase 3 protocol amendment in head and neck cancer.
bullish 80 · impact 65